Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2003;93:438-447
Published online before print July 24, 2003, doi: 10.1161/01.RES.0000088358.99466.04
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
93/5/438    most recent
01.RES.0000088358.99466.04v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benndorf, R.
Right arrow Articles by Wieland, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benndorf, R.
Right arrow Articles by Wieland, T.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Angiogenesis
Right arrow Growth factors/cytokines
(Circulation Research. 2003;93:438.)
© 2003 American Heart Association, Inc.


Cellular Biology

Angiotensin II Type 2 Receptor Inhibits Vascular Endothelial Growth Factor–Induced Migration and In Vitro Tube Formation of Human Endothelial Cells

Ralf Benndorf, Rainer H. Böger, Süleyman Ergün, Anna Steenpass, Thomas Wieland

From the Institut für Experimentelle und Klinische Pharmakologie (R.B., R.H.B., A.S.), Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Institut für Anatomie (S.E.), Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; and Institut für Pharmakologie und Toxikologie (T.W.), Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany.

Correspondence to Dr Ralf Benndorf, Institut für Experimentelle und Klinische, Pharmakologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. E-mail benndorf{at}uke.uni-hamburg.de

Endothelial cell migration and tube formation in response to vascular endothelial growth factor (VEGF) play an important role in the process of angiogenesis. Recent data indicate that angiotensin type 2 (AT2) receptor stimulation is antiangiogenic. Therefore, we studied the effect of angiotensin II (Ang II) on VEGF-induced migration and in vitro tube formation of human endothelial cells. Ang II inhibited VEGF-induced migration of EA.hy926 cells, human coronary artery (HCA) and human dermal microvascular (HDM) endothelial cells (ECs) as well as tube formation by HDMECs. The AT2 receptor antagonist PD123,319 but not the AT1 receptor antagonist losartan blocked the inhibitory effect of Ang II. The inhibitory effect of Ang II on VEGF-induced migration of endothelial cells was mimicked by the specific AT2 receptor agonist CGP-42112A. The phosphorylation of Akt and its downstream effector endothelial NO synthase (eNOS) is pivotal to VEGF-induced angiogenesis. We therefore investigated the effect of Ang II on VEGF-induced Akt and eNOS phosphorylation. Ang II diminished the VEGF-induced phosphorylation of Akt and eNOS in endothelial cells, whereas the autophosphorylation of VEGF receptors was unaffected. CGP-42112A again mimicked and PD123,319 but not losartan blocked the inhibitory effect of Ang II. Treatment of endothelial cells with pertussis toxin (PTX) totally abolished the AT2 receptor–mediated inhibition of VEGF-induced endothelial cell migration and blocked the inhibition of Akt and eNOS phosphorylation. In conclusion, this study indicates that AT2 receptor stimulation inhibits VEGF-induced endothelial cell migration and tube formation via activation of a PTX-sensitive G protein. These findings may explain the reported antiangiogenic properties of the AT2 receptor.


Key Words: angiogenesis • migration • angiotensin II • AT2 receptor




This article has been cited by other articles:


Home page
Physiol. Rev.Home page
C. Clapp, S. Thebault, M. C. Jeziorski, and G. Martinez De La Escalera
Peptide Hormone Regulation of Angiogenesis
Physiol Rev, October 1, 2009; 89(4): 1177 - 1215.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. A. Benndorf, E. Schwedhelm, A. Gnann, R. Taheri, G. Kom, M. Didie, A. Steenpass, S. Ergun, and R. H. Boger
Isoprostanes Inhibit Vascular Endothelial Growth Factor-Induced Endothelial Cell Migration, Tube Formation, and Cardiac Vessel Sprouting In Vitro, As Well As Angiogenesis In Vivo via Activation of the Thromboxane A2 Receptor: A Potential Link Between Oxidative Stress and Impaired Angiogenesis
Circ. Res., October 24, 2008; 103(9): 1037 - 1046.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
E. I. Ager, J. Neo, and C. Christophi
The renin-angiotensin system and malignancy
Carcinogenesis, September 1, 2008; 29(9): 1675 - 1684.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K.-H. Kang, S.-Y. Park, S. B. Rho, and J.-H. Lee
Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis
Cardiovasc Res, July 1, 2008; 79(1): 150 - 160.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. Xu, R. E. Perez, I. I. Ekekezie, A. Navarro, and W. E. Truog
Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell death
Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L17 - L23.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Hu, A. Dandapat, and J. L Mehta
Angiotensin II Induces Capillary Formation From Endothelial Cells Via the LOX-1 Dependent Redox-Sensitive Pathway
Hypertension, November 1, 2007; 50(5): 952 - 957.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Rakusan, Z. Chvojkova, P. Oliviero, I. Ostadalova, F. Kolar, C. Chassagne, J.-L. Samuel, and B. Ostadal
ANG II type 1 receptor antagonist irbesartan inhibits coronary angiogenesis stimulated by chronic intermittent hypoxia in neonatal rats
Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1237 - H1244.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
F. Feihl, L. Liaudet, B. Waeber, and B. I. Levy
Hypertension: A Disease of the Microcirculation?
Hypertension, December 1, 2006; 48(6): 1012 - 1017.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Donnini, R. Solito, A. Giachetti, H. J. Granger, M. Ziche, and L. Morbidelli
Fibroblast Growth Factor-2 Mediates Angiotensin-Converting Enzyme Inhibitor-Induced Angiogenesis in Coronary Endothelium
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 515 - 522.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. H. Strauss and A. S. Hall
Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox
Circulation, August 22, 2006; 114(8): 838 - 854.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. C. Petersen, D. H. Munzenmaier, and A. S. Greene
Angiotensin II infusion restores stimulated angiogenesis in the skeletal muscle of rats on a high-salt diet
Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H114 - H120.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. Pladys, F. Sennlaub, S. Brault, D. Checchin, I. Lahaie, N. L. O. Le, K. Bibeau, G. Cambonie, D. Abran, M. Brochu, et al.
Microvascular rarefaction and decreased angiogenesis in rats with fetal programming of hypertension associated with exposure to a low-protein diet in utero
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2005; 289(6): R1580 - R1588.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
V. L. M. Herrera, L. R. B. Ponce, P. D. Bagamasbad, B. D. VanPelt, T. Didishvili, and N. Ruiz-Opazo
Embryonic lethality in Dear gene-deficient mice: new player in angiogenesis
Physiol Genomics, November 17, 2005; 23(3): 257 - 268.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
R. H Boger, E. Schwedhelm, R. Maas, S. Quispe-Bravo, and C. Skamira
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study
Vascular Medicine, July 1, 2005; 10(1_suppl): S97 - S102.
[Abstract] [PDF]


Home page
Vasc MedHome page
R. H Boger, E. Schwedhelm, R. Maas, S. Quispe-Bravo, and C. Skamira
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study
Vascular Medicine, May 1, 2005; 10(2_suppl): S97 - S102.
[Abstract] [PDF]


Home page
HypertensionHome page
B. L. Falcon, S. J. Veerasingham, C. Sumners, and M. K. Raizada
Angiotensin II Type 2 Receptor-Mediated Gene Expression Profiling in Human Coronary Artery Endothelial Cells
Hypertension, April 1, 2005; 45(4): 692 - 697.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Perlegas, H. Xie, S. Sinha, A. V. Somlyo, and G. K. Owens
ANG II type 2 receptor regulates smooth muscle growth and force generation in late fetal mouse development
Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H96 - H102.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]


Home page
Am. J. Pathol.Home page
H. Takeda, Y. Katagata, Y. Hozumi, and S. Kondo
Effects of Angiotensin II Receptor Signaling during Skin Wound Healing
Am. J. Pathol., November 1, 2004; 165(5): 1653 - 1662.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Ichiki
Role of Renin Angiotensin System in Angiogenesis: It Is Still Elusive
Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 622 - 624.
[Full Text] [PDF]